OUTLOOK THERAPEUTICS, INC. Unrecognized Tax Benefits, Period Increase (Decrease)
OUTLOOK THERAPEUTICS, INC. (OTLK) reported Unrecognized Tax Benefits, Period Increase (Decrease) of -$1.55 million for the 12-month period ending 2025-09-30, per its 10-K filed 2025-12-19.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease · last filed 2025-12-19
- OUTLOOK THERAPEUTICS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2025 was -$1.55M.
- OUTLOOK THERAPEUTICS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2024 was $0.00.
- OUTLOOK THERAPEUTICS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2023 was $0.00.
- OUTLOOK THERAPEUTICS, INC. unrecognized tax benefits, period increase (decrease) for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Period Increase (Decrease) 12 month |
|---|---|
| 2025-09-30 | -$1.55M 10-K · filed 2025-12-19 |
| 2024-09-30 | $0.00 10-K · filed 2025-12-19 |
| 2023-09-30 | $0.00 10-K · filed 2024-12-27 |
| 2022-09-30 | $0.00 10-K · filed 2023-12-22 |
| 2021-09-30 | $0.00 10-K · filed 2022-12-29 |
| 2020-09-30 | -$2.81K 10-K · filed 2021-12-23 |
| 2019-09-30 | $3.31K 10-K · filed 2020-12-23 |
| 2018-09-30 | -$496.00K 10-K · filed 2019-12-19 |
| 2017-09-30 | $497.50K 10-K · filed 2018-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |